Intellia Therapeutics Inc Stock
There is an upward development for Intellia Therapeutics Inc compared to yesterday, with an increase of €0.12 (1.590%).
With 25 Buy predictions and 4 Sell predictions Intellia Therapeutics Inc is one of the favorites of our community.
With a target price of 26 € there is potential for a 232.91% increase which would mean more than doubling the current price of 7.81 € for Intellia Therapeutics Inc.
So far the community has only identified positive things for Intellia Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 1.590% | -6.699% | 2.753% | -37.471% | -32.354% | -78.838% | -82.083% |
| Chromadex Corp | -1.800% | 0.000% | -4.310% | -4.310% | 7.767% | 271.113% | 32.143% |
| Polynovo Ltd | -2.210% | 0.758% | 5.556% | -45.041% | -45.041% | -48.047% | -71.581% |
| Cardio3 Biosciences S.A. | -11.080% | -4.464% | -9.577% | -76.739% | -75.719% | -82.186% | -97.597% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at HC Wainwright from $18.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set